These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 26779796)

  • 1. The ABSORB III Trial: Potential New Concepts for Intracranial Atherosclerosis in the Post-SAMMPRIS Era.
    Aoun RJ; Sattur MG; Panchanathan RS; Bendok BR
    Neurosurgery; 2016 Feb; 78(2):N19-20. PubMed ID: 26779796
    [No Abstract]   [Full Text] [Related]  

  • 2. Bioresorbable Vascular Scaffolds--Will Promise Become Reality?
    Byrne RA
    N Engl J Med; 2015 Nov; 373(20):1969-71. PubMed ID: 26457446
    [No Abstract]   [Full Text] [Related]  

  • 3. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.
    Ellis SG; Kereiakes DJ; Metzger DC; Caputo RP; Rizik DG; Teirstein PS; Litt MR; Kini A; Kabour A; Marx SO; Popma JJ; McGreevy R; Zhang Z; Simonton C; Stone GW;
    N Engl J Med; 2015 Nov; 373(20):1905-15. PubMed ID: 26457558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioresorbable Scaffold　- Taking the Edge Off?
    Tanaka A
    Circ J; 2016 Apr; 80(5):1100-1. PubMed ID: 27026259
    [No Abstract]   [Full Text] [Related]  

  • 5. Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
    Ishibashi Y; Muramatsu T; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Cho YK; Garcia-Garcia HM; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; McClean D; de Sousa Almeida M; Wasungu L; Miquel-Hebert K; Dudek D; Chevalier B; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1053-1063. PubMed ID: 26205444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioresorbable Scaffolds for Coronary Artery Disease.
    Nathan A; Kobayashi T; Kolansky DM; Wilensky RL; Giri J
    Curr Cardiol Rep; 2017 Jan; 19(1):5. PubMed ID: 28108898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect on death of scaffold thrombosis versus stent thrombosis.
    Lafont A; Mennuni MG
    Lancet; 2016 May; 387(10034):2198. PubMed ID: 27302028
    [No Abstract]   [Full Text] [Related]  

  • 8. A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial.
    de Winter RJ; Katagiri Y; Asano T; Milewski KP; Lurz P; Buszman P; Jessurun GAJ; Koch KT; Troquay RPT; Hamer BJB; Ophuis TO; Wöhrle J; Wyderka R; Cayla G; Hofma SH; Levesque S; Żurakowski A; Fischer D; Kośmider M; Goube P; Arkenbout EK; Noutsias M; Ferrari MW; Onuma Y; Wijns W; Serruys PW
    Lancet; 2018 Feb; 391(10119):431-440. PubMed ID: 29203070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial.
    Onuma Y; Serruys PW; Ormiston JA; Regar E; Webster M; Thuesen L; Dudek D; Veldhof S; Rapoza R
    EuroIntervention; 2010 Sep; 6(4):447-53. PubMed ID: 20884431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis after revascularization for left main coronary artery disease: insights from the crystal ball.
    Byrne RA; Kastrati A
    Eur Heart J; 2015 May; 36(20):1212-5. PubMed ID: 25784753
    [No Abstract]   [Full Text] [Related]  

  • 13. A case of true left main bifurcation treated with bioresorbable everolimus-eluting stent v-stenting.
    Sato K; Latib A; Panoulas VF; Naganuma T; Miyazaki T; Colombo A
    JACC Cardiovasc Interv; 2014 Aug; 7(8):e103-4. PubMed ID: 25086841
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomised comparison of a bioresorbable everolimus-eluting scaffold with a metallic everolimus-eluting stent for ischaemic heart disease caused by de novo native coronary artery lesions: the 2-year clinical outcomes of the ABSORB II trial.
    Chevalier B; Onuma Y; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; Smits PC; Kumar R; Wasungu L; Serruys PW
    EuroIntervention; 2016 Oct; 12(9):1102-1107. PubMed ID: 27564310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: rationale and design of the randomised TROFI II study.
    Räber L; Onuma Y; Brugaletta S; Garcia-Garcia HM; Backx B; Iñiguez A; Okkels Jensen L; Cequier-Fillat À; Pilgrim T; Christiansen EH; Hofma SH; Suttorp M; Serruys PW; Sabaté M; Windecker S
    EuroIntervention; 2016 Jul; 12(4):482-9. PubMed ID: 26342471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the Everolimus-eluting Bioresorbable Scaffold in Coronary Atherosclerosis.
    Campos CM; Garcia-Garcia HM; Muramatsu T; de Araujo Gonçalves P; Onuma Y; Dudek D; Thuesen L; Webster MW; Kitslaar P; Veldhof S; Reiber JH; Nieman K; Ormiston JA; Serruys PW
    Rev Esp Cardiol (Engl Ed); 2016 Feb; 69(2):109-16. PubMed ID: 26739828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical challenge of disappearing stents.
    Finn AV; Virmani R
    Lancet; 2016 Feb; 387(10018):510-512. PubMed ID: 26597772
    [No Abstract]   [Full Text] [Related]  

  • 18. Will ABSORB III change my practice? Everolimus-eluting bioresorbable scaffolds for coronary artery disease.
    Cook S; Nef H; Capodanno D; Tamburino C; Baumbach A
    EuroIntervention; 2016 Aug; 12(6):801-4. PubMed ID: 27542795
    [No Abstract]   [Full Text] [Related]  

  • 19. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of stent thrombosis with bioresorbable vascular scaffolds.
    Shah R; Ramos-Bondy B; Mizeracki A
    Lancet; 2016 May; 387(10031):1903. PubMed ID: 27203646
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.